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Influence of a history of smoking on short term
(six month) clinical and angiographic outcome
after successful coronary angioplasty
A G Violaris, A Thury, E Regar, R Melkert, P W Serruys
Abstract
Objectives—To assess the influence of smoking on restenosis after coronary angioplasty.
Design and patients—The incidence of smoking on restenosis was investigated in 2948
patients. They were prospectively enrolled in four major restenosis trials in which quantitative
angiography was used before and immediately after successful angioplasty and again at six
months.
Results—Within the study population there were 530 current smokers, 1690 ex-smokers, and
728 non-smokers. Smokers were more likely to be men (85.9% v 87.5% v 65.3%, current v ex-
v non-, p < 0.001), to be younger (54.0 (9.0) v 57.0 (9.1) v 59.9 (9.4) years, p < 0.001), to have
peripheral vascular disease (7.2% v 5.5% v 2.3%, p < 0.001), and have sustained a previous
myocardial infarction (42.9% v 43.9% v 37.9%, p = 0.022), but were less likely to be diabetic
(9.1% v 9.5% v 12.6%, p = 0.043) or hypertensive (24.9% v 29.3% v 37.2, p < 0.001). There
was no significant diVerence in the categorical restenosis rate (> 50% diameter stenosis) at six
months (35.28% v 35.33% v 37.09%, current v ex- v non-), or the absolute loss (0.29 (0.54) v
0.33 (0.52) v 0.35 (0.55) mm, respectively; p = 0.172).
Conclusions—Although smokers have a lower incidence of known predisposing risk factors for
atherosclerosis, they require coronary intervention almost six years earlier than non-smokers and
three years earlier than ex-smokers. Once they undergo successful coronary angioplasty, there
appears to be no evidence that smoking influences their short term (six month) outcome, but
because of the known long term eVects of smoking, patients should still be encouraged to discon-
tinue the habit.
(Heart 2000;84:299–306)
Keywords: coronary angioplasty; smoking; restenosis; quantitative angiography
Restenosis after successful coronary angio-
plasty remains a major limitation of the
technique.1 2 Necropsy examination and recent
intracoronary ultrasound studies suggest that it
involves a combination of slow elastic recoil,
vessel remodelling, thrombus incorporation,
and late myointimal hyperplasia.2–4 Cigarette
smoking can theoretically be involved in any of
these mechanisms. Studies have shown that
cigarette smoke can inhibit prostacyclin pro-
duction by the vascular endothelial cells,5
impair endothelial function,6 activate platelets,7
and lower the baseline fibrinolytic activity in
blood,8 thus enhancing platelet aggregation
and thrombosis,6 9 all of which may be involved
in the restenosis process. Cigarette smoke and
its constituents can also cause acute coronary
vasoconstriction,10 substantially altering local
flow dynamics at the angioplasty site and caus-
ing increased platelet deposition and local
thrombus formation,11 which further increases
the possibilities of acute occlusion and long
term restenosis. These theoretical considera-
tions, and the large body of experimental and
clinical evidence linking smoking habits with
atherosclerosis, myocardial infarction, unstable
angina, and sudden death,12 13 have led to
several studies on the role of smoking on rest-
enosis after successful coronary angioplasty.14–19
The results have been conflicting, however,
with two studies suggesting a positive
relation14 15 and others suggesting no
relation16–19 between the two.
Discrepancies between studies have arisen
for various reasons. First, most have been
retrospective analyses using small numbers of
patients and thus subject to type B error.15 Sec-
ond, they have almost invariably used visual
assessment of the angiogram which has been
shown to have wide interobserver and intraob-
server variability.20 Third, the angiographic fol-
low up rate has been generally poor and follow
up has usually been performed for recurrence
of symptoms,14 16 thus introducing an impor-
tant selection bias.
We attempted to overcome these limitations
by using a validated automated edge detection
technique in a large series of patients undergo-
ing successful balloon angioplasty and routine
follow up angiographic assessment at a prede-
termined time interval. The aim of our study
was to analyse the association between the
information on smoking status available at the
time of the procedure and the six month
outcome.
Methods
PATIENTS
The study population comprised 2948 patients
with significant primary stenoses in native cor-
onary arteries who were prospectively enrolled
into four major restenosis trials: CARPORT
(coronary artery restenosis prevention on
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repeated thromboxane-antagonism study),
PARK (post-angioplasty restenosis ketanserin
trial), MERCATOR (multicentre European
research trial with cilazapril after angioplasty to
prevent transluminal coronary obstruction and
restenosis), and MARCATOR (multicenter
American research trial with cilazapril after
angioplasty to prevent transluminal coronary
obstruction and restenosis ).21–24 These showed
that active treatment had no eVect on resteno-
sis or clinical outcome in the first six months
after balloon angioplasty, so for the purposes of
this study the data for the active and placebo
groups were pooled. Patients were eligible for
study entry if they were symptomatic or
asymptomatic men, or women without child
bearing potential, with stable or unstable
angina pectoris, and proven angiographically
significant narrowing in one or more major
coronary arteries. Informed consent was ob-
tained in all cases before the coronary angio-
plasty procedure. Patients with developing
myocardial infarction and significant left main
coronary artery disease were excluded from the
study.
SMOKING HISTORY
A history of smoking was requested as part of
the routine work up. Patients were asked if they
had ever smoked and whether they were
continuing to smoke, and their answers were
recorded on the data sheet. Ex-smokers were
defined as patients who had ever smoked
regardless of the time when they stopped.
ANGIOPLASTY PROCEDURE AND FOLLOW UP
ANGIOGRAPHY
Coronary angioplasty was performed with a
steerable, moveable guide wire system by the
femoral route. Standard balloon catheters were
used. The choice of balloon type and brand, as
well as inflation pressure and duration, were
left to the discretion of the operator. Patients
were followed up for six months, at which time
a follow up study was performed. If symptoms
recurred within six months, coronary angio-
graphy was carried out earlier. If no definite
restenosis was present and the follow up time
was below four months, the patient was asked
to undergo further coronary arteriography at
six months.
Quantitative angiography
Three coronary angiograms in all were ob-
tained for each patient: before percutaneous
transluminal coronary angioplasty (PTCA),
after PTCA, and at angiographic follow up.
The angiograms were recorded in such a man-
ner that they were suitable for quantitative
analysis by the computer assisted coronary
angiography analysis system (CAAS) which
has been described and validated earlier.25 To
standardise the method of data acquisition and
to ensure exact reproducibility of the angio-
graphic studies, measures were taken as previ-
ously described and all angiograms were proc-
essed in a central angiographic core
laboratory.21–24 Because the computer algo-
rithm is unable to measure total occlusions, a
value of 0 mm was substituted for the mini-
mum lumen diameter and a value of 100% for
the per cent diameter stenosis before PTCA. In
these cases the post-angioplasty reference
diameter was substituted for vessel size.
Angiographic definitions used
x Vessel size refers to the reference diameter of
the relevant coronary segment and is repre-
sented by the interpolated reference diam-
eter pre-PTCA.
x Minimum luminal diameter (MLD) is the
point of maximum luminal narrowing in the
analysed segment.
x Restenosis was assessed using both a cat-
egorical and a continuous approach.26 27 For
the categorical approach we used a cut oV
point of > 50% diameter stenosis at follow
up. For the continuous approach we exam-
ined the absolute and relative loss, which
may be a better reflection of the behaviour of
the lesion during and after angioplasty, and
therefore provide a better representation of
the pathological process involved during fol-
low up.26
x Acute gain and late loss represent the
improvement in minimum luminal diameter
achieved at intervention and the absolute
change during follow up, respectively,
measured in mm:
Acute gain = MLD post-PTCA − MLD pre-
PTCA
Absolute (or late) loss = MLD post-
PTCA − MLD at follow up
x Relative gain and relative loss depict the
improvement in minimum luminal diameter
achieved at intervention and the change
during follow up respectively, normalised for
vessel size:
Relative gain = [MLD post-PTCA − MLD
pre-PTCA]/vessel size
Relative loss = [MLD post-PTCA − MLD at
follow up]/vessel size
x The absolute net gain is the MLD at follow
up − MLD pre-PTCA.
x The net gain index is the net gain normalised
for the vessel size:
Net gain index = [MLD at follow up − MLD
pre-PTCA]/vessel size
x The loss index is the late loss expressed as a
fraction of the acute gain (loss/gain).
STATISTICAL ANALYSIS
Data were analysed using the SAS statistical
software package. All values are expressed as
mean (SD). DiVerences in categorical variables
were assessed using the ÷2 test. Analysis of vari-
ance was used to assess diVerences in continu-
ous variables between the three groups. When-
ever the diVerence between two of the three
subgroups was tested, Bonferroni correction
was applied. Comparisons of ranked variables
(clinical end points) were tested using the
Kruskal–Wallis test. The diVerence in event-
free survival time between the three groups was
evaluated using the Kaplan–Meier method
with the log rank and Wilcoxon tests. As multi-
ple lesions within a given patient are not inde-
pendent with respect to smoking, a patient
based analysis was performed, using a single
randomly selected lesion in patients with mul-
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tivessel angioplasty. To study the relation
between a binary outcome variable (the occur-
rence of a clinical event) and multiple categori-
cal and continuous determinants, multiple
logistic regression analysis was used. To study
the relation between continuous outcome vari-
ables and multiple categorical and continuous
determinants, multiple linear regression analy-
sis was used. Probability values of p < 0.05
were considered significant.
Results
BASELINE PATIENT CLINICAL CHARACTERISTICS
The study population comprised 2948 patients
(3581 lesions, 1.22 lesions/patient) who suc-
cessfully completed the study and had follow
up quantitative angiography. The overall angio-
graphic restudy rate was 86% of all patients
undergoing successful PTCA. Within the study
population there were 728 patients who had
never smoked (889 lesions), 1690 patients who
were ex-smokers (2057 lesions), and 530
patients who were still smoking (635 lesions) at
the time of the index procedure.
The clinical and angiographic characteristics
of the three groups are summarised in tables 1
and 2. There were notable diVerences in the
baseline demographic characteristics of the
three groups. There was a significantly higher
proportion of men in the two smoking catego-
ries, and they were also younger. In addition
they were more likely to have had a previous
myocardial infarct and a history of peripheral
vascular disease. Smokers were also less likely
to be diabetic or to have a history of
hypertension. There were pronounced diVer-
ences in anginal class, with smokers more likely
to have angina in Canadian Cardiovascular
Society (CCS) class IV and in drug treatment,
with smokers and ex-smokers more likely to be
taking calcium antagonists and aspirin. Hae-
matologically, smokers were distinguished by
having higher haemoglobin concentrations,
packed cell volumes, and white cell counts.
CLINICAL FOLLOW UP
One hundred and eight (20.3%) of the current
smokers, 375 (22.2%) of the previous smokers,
and 185 (25.4%) of the non-smokers had a
clinical end point (redo PTCA, coronary artery
bypass grafting (CABG), acute myocardial inf-
arction, or death) during follow up
(p = 0.085). When we compared the event-free
survival using the log rank test the p value was
0.088, while the Wilcoxon test, which places
more emphasis on early events, gave a compa-
rable p value of 0.095. The individual compo-
nents for current, ex-, and non-smokers were:
death, 0% v 0.12% v 0.55%; myocardial
infarction, 2.64% v 2.66% v 3.57%; coronary
artery bypass grafting, 1.89% v 2.66% v
2.75%; and re-PTCA, 15.85% v 16.75% v
18.54%, respectively (p = 0.057). The time
course of clinical end points is summarised in
fig 1. The mean (SD) time to clinical follow up
was similar in the three groups (current smok-
ers 163 (44), ex-smokers 162 (44), non-
smokers 161 (45)).
To exclude the possibility that selection bias
influenced our results we also examined the
clinical end points in the 14% of the population
in whom no quantitative angiographic meas-
Table 1 Baseline clinical characteristics of current smokers, ex-smokers, and non-smokers
Non-smokers Ex-smokers Current smokers Significance level
Number of patients 728 1690 530
Men 65.3% 87.5%* 85.9%* 0.000
Age (years) (mean (SD)) 59.9 (9.4) 57.0 (9.1)* 54.0 (9.0) 0.000
Previous myocardial infarct 37.9% 43.9%* 42.9%* 0.022
Previous CABG 3.6% 4.6% 4.0% 0.470
Previous PTCA 4.1% 5.1% 5.5% 0.486
Diabetes mellitus 12.6% 9.5%* 9.1%* 0.043
IDDM 1.8% 0.7%* 0.4%* 0.009
History of hypertension 37.2% 29.3%* 24.9%* 0.000
History of hypercholesterolaemia 32.0% 31.5% 31.9% 0.965
History of PVD 2.3% 5.5%* 7.2%* 0.000
Anginal class
None 6.3% 5.8% 4.3%
CCS class I 9.8% 11.7% 11.3%
CCS class II 34.6% 32.6% 29.4%
CCS class III 31.5% 29.9% 29.1%
CCS class IV 17.9% 20.2% 25.9%*† 0.032
Duration of angina (weeks) (mean (SD)) 120 (208) 111 (209) 94 (202) 0.205
Days since deterioration of angina (mean
(SD))
80 (198) 79 (181) 65 (127) 0.524
Drug treatment at screening
â Blockers 52.3% 49.2% 51.5% 0.321
Calcium antagonists 65.4% 70.4%* 72.3%* 0.016
Nitrates 62.1% 66.7% 66.2% 0.659
Anticoagulants 0.8% 1.5% 2.5% 0.067
Platelet inhibitor 64.3% 63.5% 67.7% 0.203
Aspirin 77.9% 83.4%* 83.1%* 0.032
Persantin 10.6% 11.6% 15.2% 0.121
Laboratory investigations (mean (SD))
Haemoglobin (g/dl) 8.72 (0.86) 8.89 (0.80) 8.99 (0.86)* 0.000
Packed cell volume (%) 41 (4) 42 (4) 43 (4)* 0.000
White cell count (G/l) 7.05 (2.94) 7.34 (2.09) 8.26 (2.24)*† 0.000
Platelet count (G/l) 260 (80) 255 (66) 258 (70) 0.276
Total cholesterol (mmol/l) 5.88 (1.31) 5.80 (1.21) 5.88 (1.20) 0.249
HDL cholesterol (mmol/l) 1.20 (0.34) 1.13 (0.56) 1.11 (0.69) 0.477
LDL cholesterol (mmol/l) 4.15 (1.18) 4.16 (1.33) 3.94 (1.20) 0.519
*p < 0.05 v non-smokers; †p < 0.05 v ex-smokers.
CABG, coronary artery bypass graft; HDL, high density lipoprotein; IDDM, insulin dependent diabetes mellitus; LDL, low density
lipoprotein; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease.
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urements were available, either before or after
PTCA or at follow up, and who were therefore
excluded from the study population. Of these
patients 22.5% of the current smokers, 22.6%
of the previous smokers, and 23.2% of the
non-smokers had a clinical end point during
follow up (redo PTCA, CABG, acute myocar-
dial infarction, or death). The diVerence was
not significant (p = 0.99). The individual com-
ponents of worse clinical end point such as
death, myocardial infarction, coronary artery
bypass grafting, and re-PTCA were 7.14%,
2.04%, 6.12%, and 7.14%, respectively, for
current smokers; 3.17%, 4.37%, 4.76%, and
10.32% for ex-smokers; and 0.89%, 3.57%,
7.14%, and 11.61% for non-smokers. The dif-
ferences in the individual clinical end points
between the three groups were not significant
(p = 0.340).
QUANTITATIVE ANGIOGRAPHIC ANALYSIS AND
CORONARY ANGIOPLASTY PROCEDURE
A mean of 2.12 matched angiographic projec-
tions per lesion had satisfactory quantitative
analysis performed at the central angiographic
core laboratory before and after PTCA and at
follow up. The distribution of lesions was
significantly diVerent in the three groups, with
non-smokers having more lesions in the left
anterior descending coronary artery and less in
the right coronary artery than smokers and
ex-smokers. Non-smokers were also more
likely to have visible collaterals on baseline
angiography (table 2).
There were no significant diVerences in the
baseline quantitative angiographic measure-
ments between the three groups apart from a
slightly higher minimum lumen diameter
before PTCA in current smokers (borderline
significance, table 3). Smokers, however, re-
quired a longer duration of inflation (current)
and inflation pressure (both current and
ex-smokers) for a successful angioplasty proce-
dure (table 2). After PTCA all quantitative
angiographic measurements and derived vari-
ables were similar for the three groups (table 3,
fig 2), again confirming the similarity in acute
angiographic outcome.
At the six month angiographic follow up
there was no significant diVerence in angio-
Table 2 Baseline angiographic and procedural data on current smokers, ex-smokers, and non-smokers
Non-smokers Ex-smokers Current smokers Significance value
Number of diseased vessels 0.347
1-VD 65.0% 62.9% 66.0%
2-VD 26.4% 29.5% 25.7%
3-VD 7.8% 7.2% 7.6%
Lesion location
LAD 50.6%*† 42.0% 41.1% 0.002
LCx 22.8% 24.7% 23.8%
RCA 26.5%*† 33.3% 34.9% 0.002
Lesion characteristics
Total occlusion pre-PTCA 7.8% 7.5% 7.0* 0.852
Concentric 46.2% 43.8% 44.6% 0.606
Tandem lesion 3.8% 4.2% 3.9% 0.871
Multiple irregularities 8.3% 7.5% 8.4% 0.742
Branch point in stenosis 37.3% 32.2% 26.8% 0.054
Branch point in dilatation site 65.4% 65.5% 61.8% 0.635
Coronary artery bend 19.9% 19.7% 18.3% 0.772
Calcified lesion 12.5% 12.8% 10.2% 0.275
Thrombus visible (pre-or post-PTCA) 5.4% 4.5% 6.0% 0.316
Degree of collateral supply
No collaterals 78.5%*† 85.1% 87.7% 0.005
Slight (minimal perfusion) 5.9%*† 4.2% 3.1% 0.005
Medium (partial perfusion) 6.8%*† 4.4% 4.6% 0.005
Major (complete perfusion) 4.0%† 3.7% 1.6% 0.005
Not assessed 4.8%*† 2.7% 2.9% 0.005
PTCA procedure data (mean (SD))
Nominal size of largest balloon (mm) 2.87 (0.42) 2.89 (0.43) 2.87 (0.42) 0.342
Balloon to artery ratio 1.13 (0.18) 1.12 (0.18) 1.12 (0.19) 0.402
Total number of inflations 3.6 (2.6) 3.6 (2.2) 3.8 (2.4) 0.412
Total duration of inflation (s) 301 (267) 323 (264) 344 (288)* 0.021
Maximum inflation pressure (atm) 8.2 (2.5) 8.6 (2.5)* 8.7 (2.5)* 0.001
Post-PTCA result
Dissection at the dilated site 37.5% 34.2% 31.3% 0.069
Dissection type 0.255
Type A 16.0% 14.9% 15.7%
Type B 16.7% 15.1% 11.1%
Type C 4.1% 3.7% 4.0%
Type D 0.2% 0.0% 0.0%
Type E 0.2% 0.2% 0.0%
Type F 0.2% 0.0% 0.0%
Days to follow up (mean (SD)) 161 (45) 162 (44) 163 (44) 0.553
*p < 0.05 v non-smokers; †p < 0.05 v current smokers.
1, 2, 3-VD, one vessel, two vessel, three vessel disease; LAD, left anterior descending coronary artery; LCx, left circumflex coronary
artery; PTCA, percutaneous transluminal coronary angioplasty; RCA, right coronary artery.
Figure 1 Cumulative distribution curve of clinical end
points over time for current smokers, ex-smokers, and
non-smokers.
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graphic outcome between the three groups
(table 3, fig 2). The overall restenosis rate for
the study population was 35.8% using the cat-
egorical approach (> 50% stenosis at follow
up): current smokers 35.28%, ex-smokers
35.33%, non-smokers 37.09% (p = 0.687).
Additionally, the absolute and relative loss
were also similar between current smokers,
ex-smokers, and non-smokers: absolute loss,
0.29 (0.54) v 0.33 (0.52) v 0.35 (0.55) mm
(p = 0.172); relative loss, 0.12 (0.22) v 0. 13
(0.21) v 0. 14 (0.22) (p = 0.085) (table 3, fig
3).
MULTIPLE LINEAR REGRESSION ANALYSIS
We have previously shown that vessel size,
minimum lumen diameter before PTCA,
absolute gain, and location of the left anterior
descending coronary artery make a significant
contribution to late angiographic outcome.28
Adding smoking to this model did not improve
its predictive value. Least squares means for
absolute loss were 0.348, 0.311, and 0.307 for
non-smokers, ex-smokers, and current smok-
ers, respectively. The p value of adding the
variable “smoking” to the model was 0.15,
which is not significant.
To determine whether the tendency towards
improved clinical outcome in patients who
Table 3 Quantitative angiographic analyses of current smokers, ex-smokers, and non-smokers
Non-smokers Ex-smokers Current smokers Significance level
Reference diameter (mm)
Before angioplasty 2.60 (0.54) 2.65 (0.53) 2.64 (0.54) 0.116
After angioplasty 2.65 (0.52) 2.69 (0.50) 2.67 (0.51) 0.129
At follow up 2.67 (0.56) 2.71 (0.56) 2.71 (0.54) 0.200
Minimum lumen diameter (mm)
Before angioplasty 0.96 (0.40) 1.00 (0.40) 1.02 (0.38)* 0.046
After angioplasty 1.75 (0.37) 1.78 (0.36) 1.76 (0.34) 0.144
At follow up 1.40 (0.62) 1.44 (0.57) 1.46 (0.59) 0.096
DiVerences in minimum lumen diameter
Absolute gain (mm) 0.78 (0.43) 0.78 (0.41) 0.74 (0.40) 0.128
Relative gain 0.31 (0.16) 0.30 (0.16) 0.29 (0.15) 0.074
Absolute loss (mm) 0.35 (0.55) 0.33 (0.52) 0.29 (0.54) 0.172
Relative loss 0.14 (0.22) 0.13 (0.21) 0.12 (0.22) 0.085
Absolute net gain 0.43 (0.61) 0.45 (0.56) 0.45 (0.61) 0.870
Net gain index 0.16 (0.25) 0.17 (0.22) 0.16 (0.24) 0.282
Loss index 0.41 (2.37) 0.60 (5.01) 0.49 (1.34) 0.545
Percentage stenosis
Before angioplasty 62.4 (14.4) 61.8 (14.3) 60.7 (14.0) 0.142
After angioplasty 33.6 (8.4) 33.6 (8.3) 33.7 (7.8) 0.919
At follow up 47.3 (20.3) 46.2 (18.9) 45.7 (19.1) 0.278
Diameter stenosis at follow up > 50% 37.1% 35.3% 35.3% 0.687
Values are mean (SD) unless stated.
*p < 0.05 v non-smokers.
Figure 2 (A) Cumulative distribution curve of minimum
lumen diameter before and after PTCA and at follow up,
for current smokers, ex-smokers, and non-smokers.
(B) Cumulative distribution curve of percentage stenosis
before and after PTCA and at follow up for current
smokers, ex-smokers, and non-smokers.
100
75
0
50
25
100.075.025.0 50.0
Percentage stenosis
C
u
m
u
la
ti
ve
 f
re
q
u
en
cy
 (
%
)
0.0
F/U
F/U
Pre Post
Pre Post
B
100
75
0
50
25
4.003.001.00 2.00
Minimum luminal diameter (mm)
C
u
m
u
la
ti
ve
 f
re
q
u
en
cy
 (
%
)
0.00
Smoking status
Never
Ex
A
Current
Figure 3 (A) Cumulative distribution curve of absolute
loss for current smokers, ex-smokers, and non-smokers.
(B) Cumulative distribution curve of relative loss for
current smokers, ex-smokers, and non-smokers.
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smoke was related to diVerences in the under-
lying baseline characteristics, we corrected for
these variables to see whether smoking had any
significant independent predictive value. We
performed logistic regression with the above
mentioned baseline characteristics as covari-
ates, resulting in a p value for the variable
smoking of 0.122. This suggests that diVer-
ences in clinical outcome were related to
diVerences in baseline characteristics.
Discussion
Smoking is generally thought to have deleteri-
ous long term health eVects, especially on the
pulmonary and cardiovascular systems. How-
ever, the eVect of smoking on the outcome of
certain therapeutic procedures, such as coron-
ary angioplasty, is poorly understood. The aim
of our study was to analyse whether the smok-
ing habit known at the time of the procedure
aVected the long term outcome.
Our results indicate that there are pro-
nounced diVerences in baseline clinical, angio-
graphic, and procedural characteristics be-
tween smokers and non-smokers undergoing
coronary angioplasty. Smokers, despite having
a lower incidence of known predisposing risk
factors for atherosclerosis, require coronary
intervention much earlier than non-smokers,
but once they undergo successful coronary
angioplasty their short term (six month)
outcome is similar to non-smokers.
Two previous studies have suggested that
smoking may be associated with an increased
risk of restenosis.14 15 Both studies, however,
were in small patient populations, with a low
angiographic follow up rate, performed for
recurrence of symptoms, and without quantita-
tive angiographic analysis. Using a large patient
population with a high quantitative angio-
graphic follow up rate at a predetermined six
month time interval, our study has shown that
smoking—a risk factor for atherosclerosis in
general—is not a significant risk factor for res-
tenosis.
There are several possible reasons for this.
First, although cigarette smoking has been
shown to be a risk factor for atherosclerosis,
this is over the course of years,12 13 whereas
careful serial quantitative angiographic studies
have shown that restenosis occurs in the first
three to six months after intervention.1 Thus
cigarette smoking may have little influence on
the process over this short time frame. Second,
the mechanisms of restenosis are still incom-
pletely understood and are likely to involve dif-
fering contributions of slow elastic recoil,
thrombus incorporation, vessel remodelling,
and myointimal hyperplasia in each individual
patient.2–4 Cigarette smoking is unlikely to
influence all of these mechanisms. Third, it is
possible that the sudden withdrawal of ciga-
rettes during and immediately after the proce-
dure in the smokers may have had some
favourable eVect on vascular or haematological
systems29 which discouraged local platelet
deposition, mural thrombus formation, and
consequent restenosis. Fourth, there may be
substantive diVerences in plaque characteris-
tics between smokers and non-smokers, which
could ameliorate any thrombogenicity associ-
ated with smoking. In support of this are the
higher inflation pressures and duration of
inflation required for successful dilatation of
the atherosclerotic plaque in the smoking
group, and also the published reports suggest-
ing that lesions in smokers have a higher
content of collagen30 and that the type of lesion
that precipitates myocardial infarction in
smokers is less severe and possibly generated
by a diVerent mechanism.29 31
DIFFERENCES IN BASELINE CHARACTERISTICS
There were significant diVerences in the
baseline clinical, angiographic, and procedural
characteristics between the smoking classes
which could have been responsible for, or asso-
ciated with, the outcome of the procedure.
Smokers were younger, more likely to be male,
to have peripheral vascular disease, and to have
had a previous myocardial infarct. Conversely,
they were less likely to have diabetes mellitus or
a history of hypertension. These diVerences in
baseline characteristics may be related to age.
For example, as smokers tend to develop
atherosclerosis at a younger age, they would be
less likely to develop diseases of the older age
group such as hypertension and diabetes.
Many epidemiological studies have, however,
also reported that smokers have significantly
lower blood pressures than ex-smokers or
non-smokers,32 but the mechanism for this
negative relation is unknown. These diVerences
in baseline clinical characteristics may have
influenced clinical and angiographic outcome
in various ways. For example, diabetic patients
are more likely to have restenosis than
non-diabetics,16 33 while dilatation of a vessel
supplying previously infarcted territory is more
likely to result in occlusion at the time of follow
up angiography.
There were also significant diVerences in
baseline haematological characteristics, with
smokers having a higher haemoglobin, packed
cell volume, and white cell count than
non-smokers, and ex-smokers somewhere in
between. There is evidence that smokers are
also more likely to have a higher fibrinogen
concentration and increased blood viscosity.34
What influence these variables may have on the
clinical and angiographic outcome after inter-
vention is unclear. Although increased fibrino-
gen concentrations have not been associated
with a higher restenosis rate in a small series,35
raised white cell counts36 are known to be
strong predictors of myocardial infarction37 and
to be a marker of important cellular injury.
There were also diVerences in the distribu-
tion of lesions, with smokers having more
lesions in the right coronary artery and fewer in
the left anterior descending artery than non-
smokers, ex-smokers being somewhere in
between. This is in keeping with other
published reports suggesting a more proximal
location of coronary lesions in hypercholes-
terolaemic non-smokers, and more distally
situated lesions in normocholesterolaemic
smokers.38 The lower incidence of left anterior
descending coronary artery lesions, with their
known higher incidence of restenosis,28 may be
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responsible for the trend towards less absolute
and relative loss in smokers, with concordance
from current smokers, through ex-smokers to
non-smokers.
There were also significant diVerences in
procedural characteristics, with lesions in
smokers requiring a longer inflation time at a
higher pressure. This suggests that there might
be diVerences in plaque characteristics be-
tween the two groups, aVecting clinical and
angiographic outcome in both a positive and a
negative way. This is supported by evidence
suggesting that smokers have a significantly
higher content of collagen in coronary end-
arterectomy specimens,30 while smoking has
also been shown to increase arterial wall
stiVness—a change that may be associated with
reduction of medial porosity and reduced flow
pulsatility.
CLINICAL IMPLICATIONS
In our study population, smokers—despite hav-
ing a lower incidence of known predisposing risk
factors for atherosclerosis, such as hypertension,
diabetes, and hypercholesterolaemia—required
coronary intervention almost six years earlier
than non-smokers and three years earlier than
ex-smokers. This was on a background of
increased risk of previous myocardial infarction
and peripheral vascular disease. According to
our results, however, there appears to be no evi-
dence that smoking at the time of the procedure
aVects the six month outcome. Therefore,
smoking should not of its own be a contraindica-
tion for coronary angioplasty.
LIMITATIONS OF THE STUDY
Our study has several limitations. First, it was a
retrospective analysis of prospectively gathered
data and hence subject to the limitations inher-
ent in any retrospective analysis. For example,
it is possible that unknown variables not exam-
ined in our logistic regression model may
account for the lack of a worse clinical and
angiographic outcome in smokers. Second, our
data only apply to successful angioplasty
procedures and to a six month follow up
period. Thus we do not know if smoking
reduces the chances of acute success or
increases the immediate acute complications of
the procedure. Additionally, although resteno-
sis is usually manifest in the first six months, we
do not know whether a longer follow up period
may in fact demonstrate progression of the
angioplasty lesion in smokers. Third, we do not
have objective verification of the patient’s self
reported smoking status as we did not
specifically assess—for example, by periodic
measurement of urinary products—whether
supposed ex-smokers had truly stopped or
whether they were continuing to smoke. This is
especially pertinent as patients may give
misleading answers in order to ensure the doc-
tor’s approval. It is also possible that, given the
large eVects of second hand smoke on arterial
function, passive smoking could have aVected
the data in the ex-smokers and to a lesser
extent the non-smokers, and thus led to an
underestimate of the eVects of smoking.
A further possibility is that our study may
have been underpowered to detect a small
enough diVerence between the groups. Given
the number of patients and the restenosis rate
(both categorical and continuous (absolute
loss)) in the non-smoker group, our study has a
power of 90% to detect a diVerence of 20% in
the smoking group for the categorical resteno-
sis rate, and 0.10 mm for the absolute loss. We
would consider both of these to be clinically
significant, but the fact remains that if the
eVect of smoking were below these levels we
would have been unable to detect it.
We also do not have information on changes
in smoking habits during the follow up period
and their possible eVect on outcome. However,
subanalysis of the 1048 patients (taking part in
the CARPORT and PARK studies), whose
smoking status was ascertained at the one and
six month follow up visit, revealed that 64 of
the 166 current smokers (38.55%) stopped
smoking by the time of the six month follow up
visit. Of these, 18 had a clinical end point com-
pared with 25 who continued to smoke. How-
ever, the numbers in this subanalysis are too
small to allow a meaningful comparison.
Ideally, future studies should include obser-
vation of the changes in smoking habits over
time as well as intravascular ultrasound assess-
ment of the acute results of intervention and
the mechanism of subsequent restenosis; by
diVerentiating between slow recoil, thrombus
formation/incorporation, and intimal hyperpla-
sia this would make it easier to show benefit
from cessation of smoking.
CONCLUSIONS
Our results indicate that smokers, despite hav-
ing a lower incidence of known predisposing
risk factors for atherosclerosis, require coron-
ary intervention almost six years earlier than
non-smokers and three years earlier than
ex-smokers. This is on a background of
increased risk from previous myocardial infarc-
tion and peripheral vascular disease. Once they
undergo successful coronary angioplasty there
appears to be no evidence that smoking
influences short term (six month) outcome.
However, because of the known long term
eVects of smoking, patients should still be
encouraged to discontinue the habit.
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